It is a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency 1 The acquisition of the treatment for ...

Growth hormone therapy improved exercise capacity, heart function, and quality of life in patients with HFrEF and growth ...

Of particular recent interest is the growth hormone (GH)/insulin-like growth factor-I (IGF-I) system. In the context of skeletal muscle homoeostasis, IGF-I is thought to mediate the majority of the ...

The following is a summary of “Endocrine response in cardiogenic shock complicating myocardial infarction: the prognostic value of growth hormone and IGF-1,” published in the May 2025 issue of Journal ...